Liver Involvement is Associated with Higher Risk of Rapidly Progressive Interstitial Lung Disease and Mortality in Anti-Melanoma Differentiation-Associated Gene 5 Antibody- Positive Dermatomyositis
Journal of Inflammation Research · 2024-05 · Volume 17 · 3101-3113
DOI: 10.2147/jir.s462721 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Inflammation Research, 2024-05. Verfasst von Xin Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, People's Republic of China. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Purpose
This study aimed to assess liver involvement and investigate its correlation with rapidly progressive interstitial lung disease (RP-ILD) and mortality in anti-melanoma differentiation-associated gene 5 antibody-positive (anti-MDA5 positive) DM patients. Patients and Methods: This retrospective study included 159 patients diagnosed with anti-MDA5 positive DM or anti-synthetase syndrome (ASyS). Clinical features and laboratory findings were compared between patients with anti-MDA5 positive DM and patients with ASyS. In the anti-MDA5 positive DM cohort, clinical features and laboratory findings between patients with liver involvement and without liver involvement were further compared. The effects of liver involvement on the overall survival (OS) and development of RP-ILD were also analyzed using Kaplan-Meier method and Cox regression analysis.
Results
Levels of serum aspartate aminotransferase (AST), alanine transaminase (ALT), γ-glutamyl transferase (γGT) and alkaline phosphatase (ALP) were all significantly higher in patients with anti-MDA5 positive DM than those in patients with ASyS. In our cohort of anti-MDA5 positive DM patents, 31 patients (34.4%) were complicated with liver involvement. Survival analysis revealed that serum ferritin >1030.0 ng/mL (p 103.0 U/l (p 49.0 U/l (p 82.0 U/l (p 133.0 U/l (p 474.0 U/l (p 2.80 μmol/l (p=0.002) predicted poor prognosis. The incidence of RP-ILD increased remarkably in patients with liver involvement compared to patients without liver involvement (58.1% vs 22.0%, p=0.001). Multivariate analysis revealed that elevated serum ALT level was an independent risk factor for mortality (HR 6.0, 95% CI 2.3, 16.2, p
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Rheumatology, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, People's Republic of China.
- Scientific Research Center and Precision Medical Institute, Xi'an Jiaotong University Second Affiliated Hospital, Xi'an, People's Republic of China.
ORCID-Profile: Xin Yang
Zitieren
APA
Yang, X., Cui, X., Yang, X., Ren, B., Cheng, X., Zhao, X., Liu, S., Tian, T., Zhao, H., Qu, L., & Li, X. (2024). Liver Involvement is Associated with Higher Risk of Rapidly Progressive Interstitial Lung Disease and Mortality in Anti-Melanoma Differentiation-Associated Gene 5 Antibody- Positive Dermatomyositis. Journal of Inflammation Research, Volume 17, 3101-3113. https://doi.org/10.2147/jir.s462721
Vancouver
Yang X, Cui X, Yang X, Ren B, Cheng X, Zhao X, et al. Liver Involvement is Associated with Higher Risk of Rapidly Progressive Interstitial Lung Disease and Mortality in Anti-Melanoma Differentiation-Associated Gene 5 Antibody- Positive Dermatomyositis. Journal of Inflammation Research. 2024;Volume 17:3101-3113. doi:10.2147/jir.s462721
BibTeX
@article{Yang2024,
author = {Yang, Xin and Cui, Xiaoguang and Yang, Xiao and Ren, Bincheng and Cheng, Xiaojing and Zhao, Xinrui and Liu, Shanshan and Tian, Tian and Zhao, Hui and Qu, Li and Li, Xueyi},
title = {Liver Involvement is Associated with Higher Risk of Rapidly Progressive Interstitial Lung Disease and Mortality in Anti-Melanoma Differentiation-Associated Gene 5 Antibody- Positive Dermatomyositis},
journal = {Journal of Inflammation Research},
year = {2024},
volume = {Volume 17},
pages = {3101--3113},
doi = {10.2147/jir.s462721}
}
EUVIMED